Stevanato Group (STVN)

Stevanato Group occupies a distinctive position in the pharmaceutical supply chain. It does not develop drugs or chase blockbuster indications. Instead, it supplies the critical infrastructure that enables modern biologic and injectable therapies to reach patients safely, reliably and at scale. In an industry progressively dominated by biologics, self-administered injectables and high-value specialty medicines, this supplier niche has emerged as an opportunity for durable growth and strong pricing power.

Beneath the surface of this secular narrative lies a more nuanced story about management execution, capital allocation, margin dynamics, and return on invested capital (ROIC). As investors evaluate Stevanato not just as a beneficiary of injectable drug megatrends, but as a long-term compounder, these operational and financial metrics become central to the investment thesis.

Stevanato’s management team has steered the company through several defining transitions: from a family-rooted Italian glassware manufacturer to a global supplier of complex packaging and delivery systems for the world’s largest drug developers.

Stevanato is a great way to play the rise of biologics and the numbers support this. Over the last 4 years, biologics grew from 21% to 41% of revenue. This coincides with the strong growth in GLP1 drugs, which account for 19-20% of STVN revenue, but it’s not just GLP1s. 60% of global injectable pipeline in clinical stages are biologics, so we can assume future medication hitting mass production to be predominantly biologics.